Pfizer epilepsy drug prices were ‘unfairly high,’ UK review finds – ET HealthWorld

By Pushkala Aripaka Britain’s competition watchdog is sticking with its view that Pfizer and Flynn Pharma broke the law by charging Britain’s public health service “unfairly high” prices for an epilepsy drug, after being asked to reassess a record fine. The drugmakers made use of a loophole so that the capsules, branded Epanutin prior to September 2012, were not subject to price regulation for branded drugs, the Competition and Markets Authority (CMA) found in its provisional review. In 2016, the CMA fined Pfizer and Flynn a record 90 million pounds…

Read More